| Title | Three-dimensional regulatory hubs support oncogenic programs in glioblastoma. |
| Publication Type | Journal Article |
| Year of Publication | 2025 |
| Authors | Breves SL, Di Giammartino DCampigli, Nicholson J, Cirigliano S, Mahmood SRaza, Lee UJin, Martinez-Fundichely A, Jungverdorben J, Singhania R, Rajkumar S, Kirou R, Studer L, Khurana E, Polyzos A, Fine HA, Apostolou E |
| Journal | Mol Cell |
| Volume | 85 |
| Issue | 7 |
| Pagination | 1330-1348.e6 |
| Date Published | 2025 Apr 03 |
| ISSN | 1097-4164 |
| Keywords | Brain Neoplasms, Cell Line, Tumor, Enhancer Elements, Genetic, Epigenesis, Genetic, Gene Expression Regulation, Neoplastic, Gene Regulatory Networks, Glioblastoma, Humans, Neoplastic Stem Cells, Promoter Regions, Genetic, Single-Cell Analysis |
| Abstract | Dysregulation of enhancer-promoter communication in the three-dimensional (3D) nucleus is increasingly recognized as a potential driver of oncogenic programs. Here, we profiled the 3D enhancer-promoter networks of patient-derived glioblastoma stem cells to identify central regulatory nodes. We focused on hyperconnected 3D hubs and demonstrated that hub-interacting genes exhibit high and coordinated expression at the single-cell level and are associated with oncogenic programs that distinguish glioblastoma from low-grade glioma. Epigenetic silencing of a recurrent hub-with an uncharacterized role in glioblastoma-was sufficient to cause downregulation of hub-connected genes, shifts in transcriptional states, and reduced clonogenicity. Integration of datasets across 16 cancers identified "universal" and cancer-type-specific 3D hubs that enrich for oncogenic programs and factors associated with worse prognosis. Genetic alterations could explain only a small fraction of hub hyperconnectivity and increased activity. Overall, our study provides strong support for the potential central role of 3D regulatory hubs in controlling oncogenic programs and properties. |
| DOI | 10.1016/j.molcel.2025.03.007 |
| Alternate Journal | Mol Cell |
| PubMed ID | 40147440 |
| PubMed Central ID | PMC12009607 |
| Grant List | R01 NS136475 / NS / NINDS NIH HHS / United States T32 HD060600 / HD / NICHD NIH HHS / United States U01 DK128852 / DK / NIDDK NIH HHS / United States |
